Extreme Immune Checkpoint Inhibitor–Associated Thrombocytosis with Concurrent C-MET Upregulation Evolution in Extensive-Stage Small Cell Lung Cancer: A Case Report

Lung cancer is a formidable adversary, and one of its most aggressive forms, known as small cell lung cancer, moves with terrifying speed. For decades, doctors have relied on chemotherapy to slow its growth, but the results were often temporary. Recently, a new class of drugs called immune checkpoint inhibitors has offered a glimmer of hope. These medications do not attack the cancer directly; instead, they remove the invisible brakes that cancer cells use to hide from the body's own immune system. By releasing these brakes, the therapy allows the immune system to recognize and destroy the tumor. However, this powerful unleashing of the immune system is a double-edged sword. Sometimes, the immune system becomes too active, turning against the body's healthy tissues in a phenomenon known as an immune-related adverse event. While these side effects can affect the skin, gut, or lungs, they rarely involve the blood, and when they do, they are usually mild.

This story centers on a 62-year-old man in Hainan, China, who received a standard treatment for extensive-stage small cell lung cancer. His case is unique because it reveals a previously unseen reaction where the treatment triggered an extreme and dangerous surge in blood platelets, a condition that had never been documented in this specific type of cancer before. Platelets are tiny cell fragments in the blood that help it clot; when their numbers rise too high, the blood can become thick and prone to forming dangerous clots. In this patient, the platelet count skyrocketed to over 1,000, a level so high that doctors had to physically filter the blood to remove the excess platelets, a procedure known as plateletpheresis. What made this case even more remarkable was the timing and the accompanying biological changes. The surge in platelets happened before the tumor began to shrink significantly, suggesting that the immune system's overreaction was driving the blood changes, not the cancer itself. Furthermore, as the treatment continued, the cancer cells changed their genetic profile, becoming more aggressive in a specific way, while the patient also developed a separate issue where his body stopped producing enough stress hormones.

The patient arrived at the hospital with a large tumor in his right lung that had spread to his liver and lymph nodes. He began a regimen combining chemotherapy with an immune therapy drug called toripalimab. For the first two months, the treatment seemed to be working as intended, but on day 71, a routine blood test revealed a startling anomaly. His platelet count had jumped to 1,033, far exceeding the normal upper limit of 350. This was not a gradual increase but a sudden, extreme spike. Because the patient also had a blood clot in a major vein and showed signs of a hypercoagulable state, where the blood is too thick and likely to clot, the medical team acted immediately. They performed therapeutic plateletpheresis, a process similar to dialysis but designed to filter out the excess platelets, to bring the count down to a safer level.

While the platelet count was the most dramatic sign, it was part of a larger storm of inflammation. Blood tests showed that the patient's body was flooded with signaling proteins called cytokines, which act as messengers for the immune system. Levels of a protein called interferon-gamma were nearly 45 times higher than normal, and ferritin, a marker of inflammation, was 20 times the usual limit. These markers pointed toward a condition called hemophagocytic lymphohistiocytosis, a severe state where the immune system becomes overactive and starts attacking the body's own cells. Although the patient did not meet every strict criterion for this condition, the combination of fever, organ enlargement, and extreme inflammation suggested an incomplete form of the disease. The doctors realized that the immune system, unleashed by the cancer treatment, was firing on all cylinders, causing both the blood disorder and the inflammation.

As the medical team managed the blood crisis, they also watched the tumor. Interestingly, the peak in platelet count occurred before the tumor showed its maximum response. By day 121, the tumor had shrunk by half, a sign that the treatment was successfully fighting the cancer. This sequence of events was crucial for the researchers. If the platelet surge were caused by the cancer growing, the blood count would have risen as the tumor grew. Instead, the platelets peaked first, and the tumor shrank later. This indicated that the extreme platelet count was a side effect of the immune system's activation, a byproduct of the body's attempt to fight the disease, rather than a sign that the cancer was winning.

During this time, the doctors also noticed a change in the cancer cells themselves. When they took a second biopsy of the tumor, they found that the cells had evolved. A specific protein on the surface of the cancer cells, known as C-MET, had increased dramatically. Initially, only 10 percent of the cells showed this protein weakly, but by the time of the second biopsy, 80 percent of the cells showed it strongly. This upregulation of C-MET is a known way for cancer to develop resistance to treatment, essentially finding a new way to grow despite the drugs. The doctors responded by adjusting the treatment plan. They switched the immune therapy drug to a different one and added a medication called anlotinib, which targets blood vessel growth and can also interfere with the C-MET pathway. This adjustment was designed to tackle both the evolving cancer and the inflammatory storm.

The complexity of the case did not end there. As the patient underwent radiation therapy to consolidate the gains made by the drugs, he developed a new set of symptoms: loss of appetite and low blood pressure. An endocrinology evaluation revealed that his body had stopped producing enough cortisol, a vital hormone that helps the body handle stress. This condition, known as secondary adrenal insufficiency, is another known side effect of immune therapy, where the immune system mistakenly attacks the pituitary gland. The patient was started on hormone replacement therapy, which quickly restored his blood pressure and appetite. This marked the fourth distinct type of side effect the patient experienced, following the blood disorder, the liver inflammation, and the cytokine storm.

The medical team managed to control the patient's condition through a combination of blood filtering, medication adjustments, and hormone replacement. The patient's tumor continued to shrink, and his blood counts stabilized. However, the case highlighted a rare and dangerous convergence of events. The extreme platelet count, the cytokine storm, the evolution of the cancer cells, and the hormone deficiency all occurred in a single patient, a sequence that had never been reported before. The researchers concluded that the immune activation driving the cancer's shrinkage was also responsible for the severe blood and hormonal side effects. They suggested that doctors treating similar patients should monitor blood platelets and inflammatory markers closely during the first few months of therapy, as these signs could warn of a severe immune reaction before it becomes life-threatening.

This case serves as a stark reminder of the delicate balance in cancer treatment. The same mechanism that allows the immune system to destroy a tumor can, in rare instances, trigger a cascade of reactions that threaten the patient's life. The patient's survival depended on recognizing these signs early and adapting the treatment strategy in real time. By switching drugs, filtering the blood, and replacing missing hormones, the team navigated a path through a complex web of biological responses. The findings suggest that while immune checkpoint inhibitors are powerful tools, they require vigilant monitoring, especially in patients with small cell lung cancer, where the disease is aggressive and the body's reaction to treatment can be unpredictable. The evolution of the cancer cells toward a more resistant form also underscores the need for ongoing research into how tumors adapt to these new therapies and how to target those adaptations effectively.